ReleaseWire

Continuous Bioprocessing Market Research: Size, Industry Analysis, Growth, and Opportunities - Forecasting to 2028

In August 2023, Sartorius collaborated with Repligen Corporation and launched the Integrated bioreactor system. This system incorporates Repligen XCell ATF upstream intensification technology into Sartorius' Biostat STR bioreactor to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

Posted: Wednesday, December 20, 2023 at 8:00 AM CST

Northbrook, IL 60062 -- (SBWire) -- 12/20/2023 --Continuous Bioprocessing Market in terms of revenue was estimated to be worth $218 million in 2023 and is poised to reach $599 million by 2028, growing at a CAGR of 22.4% from 2023 to 2028 according to a new report by MarketsandMarkets. The global continuous bioprocessing market is growing owing to factors such as favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing. The market growth could be hampered by high capital investment that could limit the entry for small players.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75067818

Browse in-depth TOC on "Continuous Bioprocessing Market"
259 - Tables
46 - Figures
273 - Pages

The chromatography systems and consumables segment accounted for the largest share by product in the continuous bioprocessing market in 2022.

By product, the continuous bioprocessing market has been categorized as chromatography systems & consumables; filtration systems & devices; bioreactors; cell culture media, cell lines, buffers, and reagents; and other products. The chromatography systems and consumables segment held the largest share of the global continuous bioprocessing market in 2022. With an increased demand for biologics, the need for intensification of the upstream and downstream process to boost productivity and lower manufacturing costs has increased. This has created a demand for multicolumn chromatography, which can be effectively operated continuously to increase output and decrease resin & buffer usage, thus ensuring optimal operations.

The monoclonal antibodies segment accounted for the largest share of the application segment in the continuous bioprocessing market in 2022.

Based on application, the continuous bioprocessing market is segmented into monoclonal antibodies, vaccines, cell and gene therapy, other applications. In 2022, the monoclonal antibodies segment accounted for the largest share of the continuous bioprocessing market. This can be attributed to the increasing demand for single use bioreactors in the manufacturing of mAbs due to low cost, low workforce requirements, and reduction in time-consuming changeover procedures and validation.

The downstream bioprocess segment accounted for the largest share of the process segment in the continuous bioprocessing market in 2022.

The continuous bioprocessing market is segmented into upstream & downstream bioprocesses. downstream bioprocess is the largest process segment of the continuous bioprocessing market. Advancements in downstream technologies such as Single-pass Tangential Flow Filtration (SPTFF) and multicolumn chromatography is expected to drive the segment growth during the forecast period.

The North American region catered for the largest share of the continuous bioprocessing market in 2022.

The continuous bioprocessing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). North America regional market held a substantial share of the continuous bioprocessing market owing to the presence of a well-established biopharmaceutical industry and major players operating in the continuous bioprocessing market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=75067818

Continuous Bioprocessing Market Dynamics:

Drivers:

1. The emergence of integrated end-to-end continuous bioprocessing is projecting the market growth

Restraints:

1. High capital investment to limit entry for smaller players

Opportunities:

1. PAT-enabled optimization of continuous bioprocesses

Challenge:

1. Operational challenges

Key Market Players of Continuous Bioprocessing Industry:

Key players in the continuous bioprocessing market include Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kühner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), Bionet (Spain), Stobbe Group (Switzerland), bbi-biotech GmbH (Germany), OmniBRx Biotechnologies (India), Cell Culture Company, LLC (US), Pierre Guérin (France), Solida Biotech GmbH (Germany), Zellwerk GmbH (Germany), 3D Biotek, LLC (US), FiberCell Systems Inc. (US), among others.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=75067818

Recent Developments:

- In August 2023, Sartorius collaborated with Repligen Corporation and launched the Integrated bioreactor system. This system incorporates Repligen XCell ATF upstream intensification technology into Sartorius' Biostat STR bioreactor to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.
- In July 2022, Cytiva expanded its operations with a new facility in Muskegon, Michigan. The new chromatography resins manufacturing site is part of Cytiva's expansion investment.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com